NewLink Genetics (NLNK) Announces 2018 Business Priorities to Support Phase 3 Pivotal Trial of Indoximod Plus PD-1 Inhibitors
Tweet Send to a Friend
NewLink Genetics Corporation (NASDAQ: NLNK) today announced Indigo301, the name of its upcoming Phase 3 trial of indoximod plus PD-1 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
